Daiwa Securities Group Inc. Increases Position in Solventum Co. (NYSE:SOLV)

Daiwa Securities Group Inc. raised its position in Solventum Co. (NYSE:SOLV) by 7.1% during the 4th quarter, HoldingsChannel.com reports. The firm owned 18,871 shares of the company’s stock after acquiring an additional 1,248 shares during the period. Daiwa Securities Group Inc.’s holdings in Solventum were worth $1,247,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of SOLV. Hotchkis & Wiley Capital Management LLC acquired a new position in Solventum in the 3rd quarter valued at about $125,488,000. Trian Fund Management L.P. lifted its holdings in shares of Solventum by 32.9% in the 3rd quarter. Trian Fund Management L.P. now owns 7,126,255 shares of the company’s stock worth $496,842,000 after acquiring an additional 1,765,676 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Solventum in the 3rd quarter worth approximately $50,948,000. Nordea Investment Management AB lifted its holdings in shares of Solventum by 189.5% in the 4th quarter. Nordea Investment Management AB now owns 659,887 shares of the company’s stock worth $43,902,000 after acquiring an additional 431,986 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Solventum in the 4th quarter worth approximately $18,583,000.

Solventum Trading Up 2.8 %

Shares of NYSE:SOLV opened at $74.31 on Friday. Solventum Co. has a 52 week low of $47.16 and a 52 week high of $85.92. The company’s 50 day moving average is $74.52 and its two-hundred day moving average is $71.14. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45. The company has a market cap of $12.85 billion and a PE ratio of 27.02.

Wall Street Analyst Weigh In

SOLV has been the topic of several recent analyst reports. The Goldman Sachs Group upped their price objective on shares of Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a report on Monday, March 3rd. Morgan Stanley upped their price objective on shares of Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday, March 5th. Bank of America upped their target price on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 26th. Mizuho upped their target price on shares of Solventum from $70.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, March 3rd. Finally, Piper Sandler upped their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a “neutral” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and one has given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.